ROSGQ (Rosetta Genomics) FCF Margin %: -356.53% (As of Jun. 2017)


What is Rosetta Genomics FCF Margin %?

Rosetta Genomics ROSGQ -99.00% FCF Margin % is -356.53% as of Jun. 2017.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Rosetta Genomics's Free Cash Flow for the six months ended in Jun. 2017 was $-5.73 Mil. Rosetta Genomics's Revenue for the six months ended in Jun. 2017 was $1.61 Mil. Therefore, Rosetta Genomics's FCF Margin % for the quarter that ended in Jun. 2017 was -356.53%.

As of today, Rosetta Genomics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Rosetta Genomics's FCF Margin % or its related term are showing as below:

ROSGQ' s FCF Margin % Range Over the Past 10 Years
Min: -115.52   Med: 0   Max: 0
Current: -115.52

ROSGQ's FCF Margin % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -1.845 vs ROSGQ: -115.52

Rosetta Genomics FCF Margin % Related Terms

Rosetta Genomics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics FCF Margin % Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,431.34 -2,773.83 -1,043.63 -208.10 -114.68

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -373.22 -145.31 -597.59 -69.63 -356.53

ROSGQ vs TEAR, IDTA, ABMC: FCF Margin % Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics FCF Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's FCF Margin % falls into.


Rosetta Genomics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Rosetta Genomics's FCF Margin for the fiscal year that ended in Dec. 2016 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2016 )/Revenue (A: Dec. 2016 )
=-10.59/9.234
=-114.68 %

Rosetta Genomics's FCF Margin for the quarter that ended in Jun. 2017 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2017 )/Revenue (Q: Jun. 2017 )
=-5.733/1.608
=-356.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -356.53% mean?
Rosetta Genomics (ROSGQ) has a FCF Margin % of -356.53% as of Jun. 2017. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' FCF Margin % too high?
Rosetta Genomics' current FCF Margin % is -356.53%.
How does Rosetta Genomics' FCF Margin % compare to TEAR and IDTA?
Rosetta Genomics' FCF Margin % of -356.53% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current FCF Margin % is -356.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current FCF Margin % of -356.53%. The current FCF Margin % is -356.53%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current FCF Margin % is -356.53% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.